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Abstract
Rationale Extended-release naltrexone (XRNT), an opioid re-
ceptor antagonist, is successfully used in the treatment of opi-
oid dependence. However, naltrexone treatment of opioid-
dependent patients may reduce striatal dopamine transporter
(DAT) availability and cause depression and anhedonia.
Objectives The aim of this study is to investigate changes in
striatal DAT availability and symptoms of depression (Beck
Depression Inventory (BDI)) and anhedonia (Snaith Hamilton
Pleasure Scale (SHAPS)) before and during XRNT treatment.
Methods At baseline, ten detoxified heroin-dependent pa-
tients and 11 matched healthy controls underwent [123I]FP-
CIT single photon emission computed tomography (SPECT)
imaging to assess striatal DAT binding. Patients underwent a
second SPECT scan 2 weeks after an intramuscular injection
with XRNT.
Results At baseline, the mean binding potential (BPND) in the
putamen was at a trend level lower and the mean BDI score
was significantly higher in heroin patients (n=10) than in
controls (n=11) (3.45±0.88 vs. 3.80±0.61, p=0.067, d=
−0.48 and 12.75±7.40 vs. 5.20±4.83, p=0.019, d=1.24, re-
spectively). Post hoc analyses in subgroups with negative
urine analyses for opioids and cocaine showed significantly
lower baseline putamen BPND in heroin patients (n=8) than
controls (n=10) (3.19±0.43 vs. 3.80±0.64, p=0.049, d=
−1.03). XRNT treatment in heroin patients was not signifi-
cantly associated with changes in striatal DAT availability
(p=0.348, d=0.48), but the mean BDI score after XRNT treat-
ment was significantly lower than before treatment (7.75±
7.21 vs. 12.75±7.40, p=0.004, d=−0.68).
Conclusions The results of this study suggest that XRNT
treatment does not reduce striatal DAT availability and has
no significant effect on anhedonia, but is associated with a
significant reduction of depressive symptoms.
Keywords Dopamine transporter . Abstinence . Addiction .
Brain imaging . In vivo . Opioid receptor
Introduction
The worldwide prevalence of opioid dependence is estimated
to be 0.2 % (Degenhardt et al. 2014) and the prevalence of
illicit opioid use 0.7 % (UNODC 2012). The main illicit opi-
oid used in Europe is heroin. Although a downward trend in
the use of heroin was suggested, existing problem users will
remain a key issue for many years to come (EMCDDA 2013).
In the Netherlands (16.7 million inhabitants), the estimated
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number of opioid-dependent people in 2012 was 14,000,
which is approximately 1 per 1000 adult inhabitants (Cruts
et al. 2013). More than 90 % of the opioid-dependent people
in the Netherlands inhale heroin, and injection of heroin is rare
(NDM 2012; Cruts et al. 2013).
In the Netherlands, about 80 % of all heroin-dependent
people is in treatment, mostly methadone maintenance
treatment (85 %) and heroin-assisted treatment (5 %)
(Cruts et al. 2013; Wisselink et al. 2013). The remaining
10 % of patients in treatment are in some kind of
abstinence-oriented program, including extended detoxifi-
cation programs followed by outpatient psychosocial sup-
port and oral naltrexone (Cruts et al. 2013). International-
ly, the focus of opioid addiction treatment is shifting to-
ward recovery-oriented drug treatment (Neale et al. 2013),
resulting in a greater emphasis on abstinence as the final
treatment goal. However, outpatient treatment with or
without oral naltrexone was associated with early treat-
ment discontinuation and very high relapse rates. As a
consequence, oral naltrexone was probably not more ef-
fective than placebo (Minozzi et al. 2011).
Extended-release naltrexone (XRNT), given as injec-
tion or implant, may be a more suitable treatment for
opioid addiction than oral naltrexone treatment due to
better compliance. XRNT implants and injections signifi-
cantly reduced heroin use (Gastfriend 2011; Lobmaier
et al. 2011) and opioid-dependent people receiving XRNT
injections had significantly more opioid-free weeks than
opioid-dependent patients who were given a placebo in-
jection (Syed and Keating 2013). Patients receiving
XRNT injections stayed in treatment longer than patients
receiving placebo injections (Lobmaier et al. 2008; Syed
and Keating 2013), and XRNT treatment was well toler-
ated (Krupitsky and Blokhina 2010; Gastfriend 2011).
Although naltrexone treatment compliance can be im-
proved by extended-release formulations, there are con-
cerns about possible side effects that may result in treat-
ment dropout, i.e., no further injections/implants. For ex-
ample, significantly higher 6β-naltrexol levels, the major
metabolite of naltrexone, were found in subjects who ex-
perienced one or more side effects (i.e., headache, nausea,
anxiety) (King et al. 1997). Moreover, the prevalence of
depression and anhedonia was found to be high among
heroin addicts (Tiurina et al. 2011). Endogenous opioids
influence motivational and stress regulatory processes and
mood regulation directly by binding to the μ-opioid re-
ceptor, which causes inhibi t ion of the gamma-
aminobutyric acid (GABA) neurons and indirectly in-
duces dopamine release in the nucleus accumbens (Koob
and Le Moal 2008). Naltrexone, which is a μ-opioid re-
ceptor antagonist, possibly disturbs normal endogenous
opioid binding leading to reduced dopamine release. The
dopamine transporter (DAT) plays an important role in
controlling the synaptic dopamine levels by removing do-
pamine from the synapse. So, when the dopamine release
is changed chronically, this may lead to changes in syn-
aptic dopamine levels, and consequently to changes in the
DAT expression (Schmitt and Reith 2010; Vaughan and
Foster 2013). Interestingly, human studies also showed
that high endogenous striatal DA release was associated
with anhedonia (Zijlstra et al. 2008) and low availability
of striatal DATs was associated with symptoms of apathy
(David et al. 2008) and depression (Sarchiapone et al.
2006; Roselli et al. 2009). Additionally, opioid-
dependent patients who were abstinent showed lower
striatal dopamine D2/3 receptors (Zijlstra et al. 2008) and
DAT availability compared to healthy controls, but it was
not clear whether this effect was reversible (Jia et al.
2005; Shi et al. 2008; Yeh et al. 2012; Liu et al. 2013).
Finally, there is evidence that chronic naltrexone admin-
istration in rats results in decrease of striatal DAT avail-
ability (Bhargava and Gudehithlu 1996). Therefore,
(chronic) naltrexone treatment may further reduce striatal
DAT availability leading to an exacerbation of existing
depressive symptoms and anhedonia in opioid-dependent
patients.
The effects of naltrexone on anhedonia in humans were
mainly assessed with self-reports of pleasure ratings. The-
se studies showed that oral naltrexone can cause anhedo-
nia in healthy controls (Murphy et al. 1990; Daniel et al.
1992; Yeomans and Gray 2002). However, although
XRNT treatment was associated with a reduction of the
hedonic properties of addictive substances (O’Brien et al.
2010), XRNT treatment did not reduce the ability to ex-
perience pleasure during natural rewarding activities in
addicted patients (O’Brien et al. 2010; Tiurina et al.
2011). In order to better understand these findings, we
conducted the first study looking at the effect of XRNT
on both striatal DAT binding and self-reported anhedonia
in detoxified heroin addicts.
Based on the literature, we hypothesize that (1) at
baseline, heroin-dependent patients have lower striatal
DAT availability and report more anhedonia and depres-
sive symptoms than healthy controls; (2) during XRNT
treatment, heroin-dependent patients show a further de-
crease in striatal DAT availability compared to baseline
and an increase in anhedonia and depression scores; (3)
plasma levels of naltrexone and its major metabolite 6β-
naltrexol in heroin-dependent patients correlate with
changes in s t r ia ta l DAT avai lab i l i ty and wi th
anhedonia/depression before and during XRNT treat-
ment; (4) at baseline and at follow-up, striatal DAT
availability is negatively correlated with anhedonia and
depression; and (5) the decrease in striatal DAT avail-
ability during treatment is associated with an increase in
anhedonia and depression.
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Methods
Subjects
Subjects were recruited between January 2013 and July 2014.
Twelve detoxified heroin-dependent patients (11 male) were
recruited from addiction treatment centers throughout the
Netherlands. Inclusion criteria were (1) diagnosis of DSM-IV
opioid dependence, (2) heroin as the main substance of abuse,
and (3) inhalation as themain route of administration of heroin.
Exclusion criteria were (1) estimated IQ <70, (2) prior or cur-
rent diagnosis of psychosis or current depression with suicidal
ideation, (3) use of medication that interferes with binding of
the DAT radiotracer, (4) use of naltrexone in the past 6 months,
(5) history of head trauma or brain surgery, (6) (planned) preg-
nancy, breastfeeding, or no acceptable method of contracep-
tion, (7) involuntary treatment, (8) medical contradictions for
XRNT, and (9) no intention to be opioid-free for a minimum of
10–14 days before starting XRNT treatment.
Eleven healthy subjects were included who had no diagno-
sis of substance dependence and were matched to the patient
group for gender, age, body mass index (BMI), and smoking
status. Healthy controls were recruited through online adver-
tisement and flyer postings. Exclusion criteria for controls were
identical to exclusion criteria for the heroin-dependent subjects.
All subjects provided written informed consent to partici-
pate in the study. The study was approved by the Ethical
Committee of the Academic Medical Centre of the University
of Amsterdam, where the study was conducted, and per-
formed in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki.
Study design
For patients, there was a 2-week heroin- and methadone-free
period between the end of detoxification and the first scanning
day in order to minimize the risk of opioid withdrawal symp-
toms after XRNT injection. To measure DAT availability
in vivo, the first [123I]FP-CIT single photon emission comput-
ed tomography (SPECT) was performed just before the
XRNT injection and the second scan was made 2 weeks after
the XRNT injection. In healthy control subjects, only one
(baseline) SPECT scan was performed. All subjects were re-
quired to have a negative urine drug screen (UDS) for opioids,
cocaine, and amphetamine on the day of the SPECT scan(s).
None of the subjects used medication that could interfere with
[123I]FP-CIT binding (Booij and Kemp 2008). A breath alco-
hol test was performed to assess acute alcohol intoxication.
Clinical assessments
DSM-IV criteria for substance use disorders, psychotic disor-
ders, and depressive disorder with suicidal ideation were
assessed with the Dutch translation of the Mini-International
Neuropsychiatric Interview (MINI; van Vliet and de Beurs
2007). Before each scan, subjects were asked to fill out self-
report questionnaires assessing depressive symptoms (Beck
Depression Inventory (BDI); Arnou et al. 2001) and anhedonia
(Snaith-Hamilton Pleasure Scale (SHAPS); Snaith et al. 1995).
On both questionnaires, a higher total score indicates more
severe depression or anhedonia, respectively. Smoking status
was assessed with the Fagerström Test for Nicotine Depen-
dence (FTND; Heatherton et al. 1991). IQ was estimated with
the Dutch Adult Reading test (Schmand et al. 1991).
Study medication
After the first SPECT scan, patients were given an intramus-
cular injection with XRNT (Vivitrol®, Alkermes, Inc., USA).
Extended-release naltrexone microspheres (Alkermes, Inc.,
USA) were administered as a 4-ml gluteal intramuscular in-
jection containing 380 mg naltrexone. After injection, patients
were kept at the research facility for 30 min to check whether
they developed opioid withdrawal symptoms and to treat them
if necessary. The second SPECT session was conducted
2 weeks after the XRNT injection. The timing of the session
coincided with peak naltrexone levels (Krupitsky and
Blokhina 2010). Plasma samples were taken on the day of
the second SPECT session to assess peak naltrexone levels
and its major metabolite 6β-naltrexol (Slawson et al. 2007).
SPECT imaging procedure
SPECT brain imaging was performed on a brain-dedicated
system. This system (Neurofocus) has 12 individual crystals
equipped with a focusing collimator and a spatial resolution of
approximately 6.5 mm full-width at half maximum through-
out the 20-cm field of view. [123I]FP-CIT, which is a well-
validated radiotracer for striatal DAT imaging (Booij et al.
1997), was injected intravenously at an approximate dose of
110 MBq. [123I] labeling and acquisition were performed as
described previously (Tissingh et al. 1998). [123I]FP-CIT (GE
Healthcare, Eindhoven, The Netherlands) had a specific activ-
ity of 750 MBq/nmol and a radiochemical purity >95 %. Im-
age acquisition was performed 3 h after injection (Booij et al.
1999). Images were corrected for attenuation and reconstruct-
ed in 3D (de Win et al. 2005; Boot et al. 2008).
Analysis of SPECT data
[123I]FP-CIT binding in the striatum was determined by ana-
lyzing the five consecutive transverse slices representing the
most intense binding in the striatum. A standard region of
interest (ROI) template (constructed according to a stereo-
tactic atlas) including two regions representing DAT bind-
ing (caudate nucleus and putamen) and one region
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representing nonspecific binding (occipital cortex) was
placed bilaterally on the images, as previously reported
(de Win et al. 2005). Also, a standard template was used
representing DAT binding in the striatum as a whole. Spe-
cific DAT versus nonspecific binding ratios (binding po-
tential (BPND); Innis et al. 2007) were calculated for cau-
date nucleus, putamen, and whole striatum using the fol-
lowing formula:
BPND ¼ mean
123I½ FP‐CITbinding inROI−mean 123I½ FP−CITbinding inoccipital cortex
mean 123I½ FP‐CITbinding inoccipital cortex
Statistical analysis
Normality of distribution of all data was tested with the
Kolmogorov-Smirnov test. Equality of variances was tested
with Levene’s test.
Group differences in baseline characteristics were assessed
using an independent samples t test when a variable was nor-
mally distributed and a Mann-Whitney U test when a variable
was not normally distributed. Correlations between BPND of
the left and right striatum was assessed using Pearson’s and
Spearman’s correlation coefficients.
BPND in ROIs and BDI and SHAPS scores were compared
between groups using an independent samples t test when a
variable was normally distributed and a Mann-WhitneyU test
when a variable was not normally distributed.
Within the patient group, analyses were performed using a
paired samples t test. Within the patient group, we calculated
Pearson’s r between naltrexone and 6β-naltrexol plasma
levels and change in BPND (in striatum, caudate, and puta-
men), BDI, and SHAPS scores between scans. Also,
Pearson’s r were calculated between BPND (in striatum, cau-
date, and putamen) and BDI scores/SHAPS scores.
We reported effect sizes (d values; Cohen 1977) for each
test because of the relatively small sample size, where d=0.2
is considered a small effect, d=0.5 a medium effect, and d=
0.8 a large effect.
All statistical analyses were performed using IBM Statistical
Package for the Social Sciences (SPSS) version 20, and statisti-
cal significance was defined as p<0.05. Given the small number
of subjects, correction for multiple testing was not performed to
prevent increased type II errors, resulting in low power.
Results
Urine drug screen
Five subjects tested positive for drugs: two heroin-dependent
patient tested positive for cocaine and opioids on both scan-
ning days, two heroin-dependent patients tested positive for
opioids on the first scanning day and one healthy control tested
positive for opioids. The healthy control, who tested positive
for opioids, indicated that he had used codeine the day before
scanning. Since cocaine interferes with [123I]FP-CIT binding
(Booij and Kemp 2008), the two patients testing positive for
cocaine were excluded from further analyses. Opioid use could
possibly influence DAT availability (Booij and Kemp 2008).
Therefore, analyses were performed twice: (1) in the first anal-
ysis, the two patients testing positive for cocaine were exclud-
ed, resulting in 10 patients and 11 controls; (2) in the second
analysis, also all subjects testing positive for opioids were left
out, resulting in 8 patients and 10 controls. Missing urinalysis
data were imputed as positive. As a consequence, one more
patient with missing urinalysis data on the day of the second
scan was excluded from some of the analyses, resulting in
seven patients for the within-patient comparison. All subjects
had a negative alcohol breath test on the scan day(s).
Sample characteristics
Demographic and clinical characteristics are displayed in
Table 1. In the first analysis, no significant differences were
found in gender, age, BMI, and smoking status (FTND) be-
tween the patients and healthy controls. After excluding pa-
tients testing positive for cocaine and opioids, differences
between groups for all characteristics even decreased, except
for FTND. Since smoking statusmay influence striatal BPND
(Danielson et al. 2011), we corrected for FTND in the
between-group analyses with SPECT data.
Binding potential (BPND) in regions of interests
In all participants, intense [123I]FP-CIT binding was observed
in the striatum bilaterally (Fig. 1). DAT availability in the left
and right caudate nucleus/putamen/total striatum were highly
correlated (r>0.85, p<0.05); therefore, the mean BPND of the
bilateral measures was calculated and used in all analyses.
In the first analysis (all subjects except the two patients
with a positive urine for cocaine), two patients did not have
a second SPECT scan: one patient withdrew consent and quit
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the study before the second SPECTscan, the other patient had
a missing urine sample on the day of the second SPECT scan,
resulting in eight patients for the within-patient comparison. In
the second analysis (all subjects except those with a positive
urine for cocaine or opioids), only one of the remaining pa-
tients did not have a second SPECTscan and was therefore not
included in within-patient comparison of BPND in ROIs be-
fore and during XRNT treatment (Table 2).
In the first analysis (including opioid positive subjects), we
did not find significant group differences in baseline BPND.
However, in the second analysis (excluding both cocaine and
opioid positive subjects), baseline BPND in the putamen of
heroin patients was significantly lower than in healthy controls
(t(16)=−2.301, p=0.049, d=−1.03). There were no significant
differences in BPND between healthy controls and heroin pa-
tients at baseline for other ROIs. Correction for FTND slightly
decreased the difference in baseline BPND between heroin-
dependent patients and healthy controls. Therefore, adjusted
p values and effect sizes are displayed in Table 2.
We found no significant differences in BPND between her-
oin patients at baseline and after 2 weeks of XRNT treatment
(Fig. 1), neither when opioid-positive patients were included
nor when opioid-positive patients were excluded from the
analysis (Table 2).
Since ourmain group of interest is heroin-dependent patients
that are abstinent during the study, further analyses (see below)
were only conducted for cocaine and opioid-free subjects.
Depression and anhedonia
At baseline, BDI scores were significantly higher for heroin-
dependent patients than for healthy controls (t(16)=2.614, p=
0.019, d=1.24), see Table 3. For heroin-dependent patients
after 2 weeks of XRNT treatment, BDI scores were
Table 1 Demographic and clinical characteristics of healthy controls and heroin patients
Demographics and clinical characteristics of cocaine-free subjects (defined as negative for cocaine on urine analysis)
Healthy controls (n=11) Heroin patients (n=10)a t (df=19)/U p value Cohen’s d
Sex (nr male) 11 10
Age (mean±SD) (years) 45.6±9.4 (range 29–56) 44.9±5.5 (range 37–53) −0.216 0.832 −0.09
Duration of heroin dependence (mean±SD) (years) N/A 16.6±8.8 (range 2–30)
Body mass index (BMI) (mean±SD) (kg/m2) 26.4±4.5 24.5±4.4 37.000 0.202 −0.42
Fagerström Test for Nicotine Dependence (FTND) 0.73±0.65 0.60±0.70 48.500 0.612 −0.19
Demographics and clinical characteristics of opioid-free subjects (defined as negative for both cocaine and opioids on urine analysis)
Healthy controls (n=10) Heroin patients (n=8) t (df=16)/U p value Cohen’s d
Sex (nr male) 10 8
Age (mean±SD) (years) 45.2±9.8 (range 29–56) 45.1±6.0 (range 37–53) −0.019 0.985 −0.01
Duration of heroin dependence (mean±SD) (years) N/A 17.0±9.5 (range 2–30)
Body Mass Index (BMI) (mean±SD) (kg/m2) 25.7±4.2 24.3±4.0 29.000 0.325 −0.35
Fagerström Test for Nicotine Dependence (FTND) 0.80±0.63 0.63±0.74 33.500 0.523 −0.25
Cohen’s d: 0.20=small, 0.50=moderate, 0.80=large (Cohen 1977)
N/A not applicable
a Excluding two patients that tested positive on cocaine use at the time of the scan
Fig. 1 [123I]FP-CIT SPECT
images (transversal slides at the
level of the striatum) of a typical
heroin-dependent patient, before
(left image) and 2 weeks after
(right image) an intramuscular
injection with XRNT (380 mg).
Note that visual analyses of the
images did not show differences
between the two conditions,
which was confirmed by the
quantitative analyses (see
BResults^ section)
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significantly lower than before treatment (t(7)=4.132, p=
0.004, d=−0.68). There was no significant difference between
groups for baseline SHAPS scores. Also, there were no sig-
nificant differences between SHAPS scores before and after
2 weeks of XRNT treatment (Table 3).
Naltrexone and 6β-naltrexol plasma levels
Plasma data were missing for one patient due to technical
reasons. No significant correlations were found between
naltrexone/6β-naltrexol plasma levels and change in BPND
(in whole striatum, caudate nucleus, and putamen), BDI and
SHAPS scores in heroin-dependent patients between scans
(supplementary data, Tables S1 and S2).
Integration of SPECT data and behavioral parameters
No significant correlations were found for striatal DAT bind-
ing and anhedonia or depression at baseline or at follow-up.
Correlations between decrease in striatal DAT binding during
treatment and increase in anhedonia and depression were not
calculated because we did not find a decrease in striatal DAT
binding nor an increase in anhedonia and depression.
Discussion
The current study is the first to assess the effects of XRNT
treatment on striatal DAT binding and self-reported depression
and anhedonia in heroin-dependent subjects. Our present re-
sults suggest that blocking of the μ-opioid receptor by XRNT
does not decrease striatal DAT binding and does not increase
self-reported anhedonia, but is associated with a significant
decrease in depressive symptoms.
In line with our first hypothesis, we found significantly
lower DAT binding at baseline in the putamen of detoxified
heroin-dependent patients with a negative urine test for opi-
oids compared to controls, which is in line with previous stud-
ies (Jia et al. 2005; Shi et al. 2008; Yeh et al. 2012; Liu et al.
2013, Table 4). This implicates that detoxified heroin patients
have lower striatal DAT availability. This reduction in DAT
availability compared to controls may be related to long-term
heroin abuse since patients and healthy controls were matched
for other variables influencing DATavailability. However, due
to the design of our study, we cannot exclude the possibility of
preexisting differences in DATavailability. Although the low-
er DAT binding in heroin-dependent patients was not signifi-
cant for the caudate nucleus and whole striatum, effect sizes
indicate moderate to large effects of long-term heroin abuse on
DAT binding, supporting the hypothesis that differences in
these areas may be found when larger sample sizes are includ-
ed (Table 4; Liu et al. 2013).
Table 2 BPND per ROI for controls and heroin patients (mean±SD)
BPND (mean±SD) for cocaine-free subjects
(defined as negative for cocaine on urine
analysis)
p value Cohen’s d
PB vs HC PB (n=10) HC (n=11)
Striatum, whole 3.64±1.00 3.82±0.63 0.139 −0.21
Caudate nucleus 3.62±0.72 3.97±0.85 0.321 −0.44
Putamen 3.45±0.88 3.80±0.61 0.067 −0.48
PO vs PB PO (n=8) PB (n=8)
Striatum, whole 3.60±0.59 3.65±1.12 0.901 −0.05
Caudate nucleus 3.60±0.62 3.62±0.81 0.965 −0.02
Putamen 3.42±0.72 3.42±0.99 0.999 0.00
BPND (mean±SD) for opioid-free subjects
(defined as negative for both cocaine
and opioids on urine analysis)
p value Cohen’s d
PB vs HC PB (n=8) HC (n=10)
Striatum, whole 3.36±0.47 3.82±0.66 0.155a −0.72a
Caudate nucleus 3.45±0.52 3.99±0.90 0.198a −0.63a
Putamen 3.19±0.43 3.80±0.64 0.049a −1.03a
PO vs PB PO (n=7) PB (n=7)
Striatum, whole 3.53±0.60 3.28±0.44 0.348 0.48
Caudate nucleus 3.55±0.65 3.39±0.53 0.579 0.27
Putamen 3.28±0.65 3.10±0.38 0.477 0.35
Cohen’s d: 0.20=small, 0.50=moderate, 0.80=large (Cohen 1977). Non-
parametric test for PB vs HC: striatum and putamen in the cocaine-free
subjects’ analyses. Parametric tests were used for all other analyses listed.
Means represent observed data that were not adjusted for FTND
PB patients at baseline, HC healthy controls, PO patients on XRNT
treatment
a Adjusted for FTND scores
Table 3 Beck Depression Inventory scores and Snaith-Hamilton Pleasure Scale scores for healthy controls and heroin patients (mean±SD) that had a
negative UDS for cocaine and opioids
HC (n=10) PB ( n=8) PO (n=8) p value (Cohen’s d)
PB vs HC PO vs PB
BDI 5.20±4.83 12.75±7.40 7.75±7.21 0.019 (1.24) 0.004 (−0.68)
SHAPS 24.00±5.74 24.88±5.22 22.75±6.71 0.742 (0.16) 0.326 (−0.35)
Cohen’s d: 0.20=small, 0.50=moderate, 0.80=large (Cohen 1977)
PB patients at baseline,HC healthy controls, PO patients on XRNT treatment, BDI Beck Depression Inventory, SHAPS Snaith-Hamilton Pleasure Scale
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One healthy control indicated that he had used paracetamol
with codeine for pain relief only on the day before scanning
(two to three tablets). Exclusion of this subject from the anal-
ysis did not change mean striatal DAT binding of healthy
controls. However, when we excluded the two heroin-
dependent subjects who had a positive urine test for opioids,
mean striatal DAT binding decreased and variation in DAT
binding (SD) halved, indicating that acute use of codeine
may not influence striatal DAT binding, while acute opioid
use (i.e., heroin) may have a significant influence on striatal
DAT binding. Indeed, acute opioid use increased striatal DA
release (Di Chiara and Imperato 1988; Wise et al. 1995) and
consequently may influence striatal DAT expression. One of
the reasons that acute administration of the opioid receptor
agonist codeine may not influence striatal DAT binding, while
other opioids may do, might be that the affinity of codeine to
the μ-opioid receptor is simply too low (Ki approximately
79 nmol/l; Raynor et al. 1993) to induce indirect changes in
DAT expression. In contrast, although heroin itself has a low
affinity for the μ-opioid receptor, once in the brain, it is hy-
droxylated to morphine (Yu 1996). Morphine has a high af-
finity for the μ-receptor (Ki approximately 14 nmol/l; Raynor
et al. 1993) and might consequently indirectly influence DAT
expression. Indeed, acute or subchronic treatment with an-
other high-affinity μ-opioid agonist, namely fentanyl (Ki
approximately 0.39 nmol/l; Raynor et al. 1993), decreased
in vivo striatal DAT binding (Bergstrom et al. 1998). Thus,
our present data may indicate that it is relevant to analyze a
homogeneous group of subjects who are all truly and fully
abstinent for opioids if one is interested to study DAT
availability.
In Table 4, we summarized the findings of DAT imaging
studies in heroin-dependent patients.
Our results from the analyses excluding subjects with a
positive urine test for opioids (i.e., lower DAT binding in the
putamen in the heroin-dependent patients) are in line with
previous studies showing lower striatal DAT binding in absti-
nent heroin-dependent patients compared to healthy controls
(Table 4: Jia et al. 2005; Shi et al. 2008; Yeh et al. 2012; Liu
et al. 2013). In contrast, when subjects with a positive urine
test for opioids were included in the analyses, our results are
more consistent with the results from Cosgrove et al. (2010)
who included heroin-dependent people testing positive for
heroin (Table 4). Also, Kish and coworkers did not show
lower DAT binding in a postmortem study in which eight
out of the nine subjects died due to a heroin intoxication (Kish
et al. 2001), although this is not in line with the results of a
recent SPECTstudy (Liang et al. 2014). This again may stress
the potential effect of current use of opioids on striatal DAT
availability, as discussed earlier. Our findings underscore the
fact that homogeneity of drug use/abstinence in the heroin-
dependent subjects is needed for a correct interpretation of
results in this field of research.
Opioids inhibit the release of dopamine, serotonin, acetyl-
choline, and norepinephrine, neurotransmitters that all may
play an important role in the pathophysiology of depression
(Miotto et al. 2002), and there is a high prevalence of depres-
sion and anhedonia in heroin-dependent patients (Tiurina et al.
2011). In line with these studies and our first hypothesis, we
found higher levels of self-reported symptoms of depression
in heroin-dependent subjects before XRNT treatment com-
pared to healthy controls. However, in contrast to our expec-
tation, no significant differences were found in anhedonic
symptoms between the heroin-dependent patients and healthy
controls at baseline. This might be explained by the fact that
our healthy controls had a higher mean score for SHAPS than
was previously reported for healthy controls (Franken et al.
2007). Another explanation may be that long-term opioid use
increases (certain) depressive symptoms but not anhedonia.
Our second hypothesis, that during XRNT treatment,
heroin-dependent patients will show a decrease in striatal
DAT binding compared to baseline and that this decrease is
associated with an increase in anhedonia and depression, was
not confirmed. This hypothesis was based on findings of a
previous in vitro rodent study (Bhargava and Gudehithlu
1996) in which a decreased striatal DAT availability after
XRNT treatment was reported using the DAT ligand
[3H]GBR 12935. Although this is the first study conducted
with [123I]FP-CIT SPECT to image DAT binding during
XRNT treatment in humans, results implicate that XRNT
treatment does not decrease DAT availability. This is consis-
tent with a recent rodent study (Zaaijer et al. 2015), in which
rats were treated with short acting naltrexone or vehicle for
10 days, and no significant difference between groups was
found in striatal DAT availability using [123I]FP-CIT storage
phosphor imaging. However, we cannot rule out influences of
XRNT on other parts of the dopaminergic system, e.g., on
dopamine receptor availability. Importantly, although studies
demonstrated that naltrexone induced anhedonia and depres-
sive symptoms in healthy volunteers (Hollister et al. 1981;
Murphy et al. 1990; Daniel et al. 1992; Yeomans and Gray
2002), our study and other studies investigating the influence
of XRNT treatment on anhedonia in heroin-dependent people
did not find a significant increase in anhedonia during XRNT
treatment (O’Brien et al. 2010; Tiurina et al. 2011). In our
study, depressive symptoms improved significantly after
XRNT treatment. This is in line with results from Dean et al.
(2006) and Mysels et al. (2011) who reported a decrease in
depressive symptoms in heroin-dependent subjects that ad-
hered to naltrexone treatment compared to baseline depressive
symptoms (Dean et al. 2006; Mysels et al. 2011). This can
either mean that XRNT treatment improves depressive symp-
toms or simply that abstinence from illicit opioid use improves
depressive symptoms caused by long-term illicit opioid use, or
that other factors are involved as well such as improvement of
personal life circumstances. Finally, it cannot be excluded that
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the reduction in depressive symptoms is a result of positive
expectations or normal fluctuations. In order to clarify this is-
sue, a randomized placebo controlled trial is needed, although
we understand the ethical issues involved in such an experi-
ment. However, whatever the reasons may be, the current study
supports previous findings that treatment with extended-release
naltrexone does not lead to or worsens depressive symptoms.
In contrast to our third hypothesis, we found no significant
correlations between naltrexone/6β-naltrexol plasma levels,
striatal DAT binding, and BDI/SHAPS scores. In addition,
contradictory to our fourth and fifth hypotheses, there was
no significant relation between striatal DAT binding and an-
hedonia or depression at baseline for healthy controls and
heroin-dependent subjects, and no relation between changes
in DAT binding and changes in depression and anhedonia for
heroin-dependent patients during XRNT treatment.
The main limitation of this study is the small sample size.
However, after excluding subjects with a positive urine test for
opioids, we found moderate to large effect sizes in the
between-group analyses, indicating that significant differ-
ences would have been found with a larger sample size
(Table 2). Another important limitation is that this study did
not include a placebo arm to control for expectations and
normal fluctuations in DAT SPECT and behavioral parame-
ters. However, given the treatment opportunities that are cur-
rently available, such a strategy raises serious medical ethical
issues. Further limitations include the following: (1) the ab-
sence of coregistration of SPECT images with MRI—
coregistration of SPECT images with MRI may have improved
the accuracy of placement of the ROIs; (2) the use of only one
particular dose of XRNT and thus no possibility to study dose-
effect relationships; (3) the use of only a single injection of
XRNT to study changes in striatal DAT binding after 2 weeks
of treatment; (4) no female subjects—sex-dependent effects on
striatal DAT availability could not be accounted for; (5) no
information on changes in personal circumstances related to
increased/decreased anhedonic and depressive symptoms; and
(6) restriction to inhalation as the route of heroin administration,
while worldwide injection is preferred over inhalation and it
could be that our results are not representative for heroin-
dependent patients who inject heroin.
In conclusion, our results suggest that XRNT treatment in
detoxified heroin-dependent patients does not decrease striatal
DAT or increase anhedonia significantly, but is associated
with a significant reduction of depressive symptoms.
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